The rules changed this year, and most articles you’ll find describe a market that no longer exists. Here’s the current state, in plain English.
For two years, compounded semaglutide and tirzepatide filled the gap left by brand-name shortages. That era is ending. With brand supply restored, the FDA moved in April 2026 to formally propose removing both drugs from the 503B bulks list, the mechanism that allowed large outsourcing facilities to produce compounded versions at scale.
503A pharmacies are state-licensed pharmacies that compound a medication for a specific patient with a specific prescription. This remains legal, and it’s how legitimate telehealth programs continue to offer compounded GLP-1 options where clinically appropriate.
503B outsourcing facilities produce compounded medications in bulk without patient-specific prescriptions. This is the pathway being closed for semaglutide and tirzepatide now that brand-name supply has recovered.
Three checks take two minutes: current LegitScript certification (searchable in their public directory), a real medical evaluation before any prescription, and fulfillment through US-licensed pharmacies. These are the exact criteria every program on GLP One Guide is verified against; it’s why we review only LegitScript-certified, doctor-supervised programs.
Partly. Patient-specific compounding through state-licensed 503A pharmacies remains legal when prescribed by a licensed clinician. Large-scale 503B outsourcing of semaglutide and tirzepatide is being phased out: in April 2026 the FDA formally proposed removing both from the 503B bulks list, with a public comment period that ran through June 29, 2026.
Yes, through programs using 503A pharmacies that fill individual, patient-specific prescriptions. Every program reviewed by GLP One Guide is LegitScript-certified and prescribes only through licensed clinicians.
No-prescription peptide websites, products shipped from overseas labeled 'for research only,' and any seller that skips a medical evaluation. The FDA has issued warning letters to telehealth companies making misleading GLP-1 claims.
Brand-name options have expanded: NovoCare offers Wegovy self-pay around $349/month, LillyDirect offers Zepbound at roughly $299 to $449/month, and two oral GLP-1 pills launched in 2026.
Find a certified program that fits you → Browse all 24 certified reviews →
This page is educational, not legal or medical advice. Regulations evolve; this reflects the public record as of August 2026. Compounded medications are prepared by licensed pharmacies but are not individually FDA-evaluated for safety or effectiveness. GLP-1 medications require a prescription and are used alongside a reduced-calorie diet and exercise.
Omzo scored highest across all 24 programs we reviewed, with flexible, adjustable, doctor-supervised care.